BridgeBio CEO Neil Kumar at BIO22 (J.T. MacMillan Photography for Endpoints News)
July 14, 2023 05:53 PM EDTUpdated July 17, 06:12 AM
R&D

Bridge­Bio's make-or-break read­out is slat­ed for Mon­day, as CEO posts a cryp­tic mes­sage about Odysseus

Kyle LaHucik

Senior Reporter

Drew Armstrong

Executive Editor

Bridge­Bio said it would share da­ta on a crit­i­cal Phase III tri­al on Mon­day morn­ing, in what’s ex­pect­ed to be a make-or-break mo­ment for the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times